Internal Medicine · Montgomery, AL
NPI
1881635480
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1301 Mulberry St
Montgomery, AL, 36106
Phone (334) 265-6153
Groups this clinician bills Medicare through
Medicare paid, 2024
$246K
30,437 services
Medicare patients, 2024
205
Average age 76
Drug cost, 2024
$2.0M
16,084 prescriptions
Company payments, 2025
$2,034
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John A Jernigan was code J1071 (injection, testosterone cypionate, 1 mg), 22,000 times for 13 patients. In total John A Jernigan billed 30,437 services in 150 codes, and Medicare paid $246K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1071 Injection, testosterone cypionate, 1 mg | Office | 22,000 | 13 | $0.02 | $374 |
| 85025 Blood Count | Office | 543 | 184 | $7.42 | $4,029 |
| 36415 Venipuncture Blood Collection | Office | 530 | 172 | $8.60 | $4,560 |
| 84100 Clinical Chemistry | Office | 398 | 173 | $4.56 | $1,816 |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 396 | 62 | $99.85 | $40K |
| 83735 Clinical Chemistry | Office | 395 | 173 | $6.43 | $2,541 |
| 99214 Office E&M - Established | Office | 286 | 146 | $78.91 | $23K |
| 80053 Clinical Chemistry | Office | 283 | 160 | $10.15 | $2,873 |
| 80048 Clinical Chemistry | Office | 271 | 149 | $7.96 | $2,157 |
| 96372 Injection Administration | Office | 271 | 68 | $8.84 | $2,395 |
| 99213 Office E&M - Established | Office | 203 | 123 | $54.07 | $11K |
| 83036 Blood Count | Office | 190 | 103 | $9.18 | $1,744 |
| 84443 Clinical Chemistry | Office | 175 | 112 | $15.88 | $2,779 |
| 80061 Clinical Chemistry | Office | 171 | 139 | $12.24 | $2,092 |
| 84439 Clinical Chemistry | Office | 164 | 110 | $8.53 | $1,399 |
By year: 2022 $183K for 38,900 services; 2023 $226K for 38,368 services; 2024 $246K for 30,437 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 543 | 184 | $7.42 | $4,029 |
| 36415 Venipuncture Blood Collection | 530 | 172 | $8.60 | $4,560 |
| 84100 Clinical Chemistry | 398 | 173 | $4.56 | $1,816 |
| 83735 Clinical Chemistry | 395 | 173 | $6.43 | $2,541 |
| 80053 Clinical Chemistry | 283 | 160 | $10.15 | $2,873 |
| 80048 Clinical Chemistry | 271 | 149 | $7.96 | $2,157 |
| 83036 Blood Count | 190 | 103 | $9.18 | $1,744 |
| 84443 Clinical Chemistry | 175 | 112 | $15.88 | $2,779 |
| 80061 Clinical Chemistry | 171 | 139 | $12.24 | $2,092 |
| 84439 Clinical Chemistry | 164 | 110 | $8.53 | $1,399 |
Medicare prescription drug claims, 2024
In 2024, the drug John A Jernigan prescribed most often to Medicare patients was Amlodipine Besylate, with 728 prescriptions and refills. In total John A Jernigan wrote 16,084 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 728 | 1,974 | 219 | $5,277 |
| Atorvastatin Calcium Generic | 724 | 2,044 | 223 | $11K |
| Potassium Chloride Generic | 552 | 1,526 | 192 | $16K |
| Metoprolol Succinate Generic | 352 | 997 | 108 | $7,028 |
| Carvedilol Generic | 344 | 932 | 105 | $3,862 |
| Alprazolam Generic | 314 | 317 | 58 | $925 |
| Pantoprazole Sodium Generic | 308 | 834 | 112 | $4,606 |
| Losartan Potassium Generic | 307 | 873 | 98 | $4,902 |
| Gabapentin Generic | 256 | 507 | 81 | $5,183 |
| Celecoxib Generic | 234 | 411 | 87 | $7,087 |
| Pravastatin Sodium Generic | 232 | 655 | 67 | $4,415 |
| Eliquis Apixaban | 229 | 303 | 50 | $170K |
| Levothyroxine Sodium Generic | 223 | 519 | 51 | $3,141 |
| Furosemide Generic | 222 | 601 | 95 | $1,483 |
| Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide | 219 | 637 | 62 | $5,265 |
Brand drugs: 2,518 claims; generic drugs: 13,521 claims; opioid claims: 268.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John A Jernigan $2,034 ($2,034 in general payments such as food, travel and fees) from 22 companies. The largest payer was Novo Nordisk Inc with $328.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 10 | $328 |
| Pfizer Inc. PFE | 13 | $226 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $200 |
| Alnylam Pharmaceuticals Inc. ALNY | 6 | $188 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $154 |
| Amgen Inc. AMGN | 6 | $151 |
| LEO Pharma Inc. | 1 | $149 |
| Lilly USA, LLC LLY | 5 | $141 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $88.72 |
| Abbott Laboratories ABT | 5 | $85.34 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.